Phase I study of oral topotecan in hematological malignancies

Miloslav Beran, Susan O'Brien, Deborah A. Thomas, Hai T. Tran, Jorge E. Cortes-Franco, Francis Giles, Elihu Estey, Hagop M. Kantarjian

Research output: Contribution to journalArticle

Abstract

Purpose: In this Phase I, dose-seeking study, we investigated the dose-limiting toxicities (DLTs) and maximal tolerated dose (MTD) of oral topotecan in patients with hematological malignancies. Experimental Design: Patients with myelodysplastic syndromes, myeloproliferative disorders, or relapsed acute myelogenous leukemia were treated with 0.6-1.9 mg/m 2/day oral topotecan for 5 consecutive days on and 2 days off, for 3 weeks (15 doses/course) followed by 2-4 weeks of rest. The DLTs occurring during the first course of treatment were considered for defining the MTD. Preliminary results of antitumor activity were assessed by examining bone marrow status and peripheral blood cell counts. Results: All 26 patients enrolled in the study were evaluable for toxicity, and 24 patients were evaluable for response. A total of 54 courses were administered. The most frequently reported nonhematological toxicities (percentage of courses) were diarrhea (57%), nausea/vomiting (50%), fatigue (24%), and mucositis (9%). DLTs included grade 3 or 4 nausea/vomiting and diarrhea at 1.9 mg/m2/day. The MTD for oral topotecan in patients with hematological malignancies was defined at 1.4 mg/m2/day. Hematological toxicity was noted in all 26 patients and with all courses but was not considered dose-limiting. Four (17%) patients achieved a complete response, and six (25%) patients experienced hematological improvement. Conclusions: Protracted administration of oral topotecan is safe and well tolerated in patients with hematological malignancies. At the dose-schedule used, single-agent oral topotecan has a definite activity in patients with myelodysplastic syndrome and acute myelogenous leukemia and warrants further investigation alone or in combination with other agents.

Original languageEnglish (US)
Pages (from-to)4084-4091
Number of pages8
JournalClinical Cancer Research
Volume9
Issue number11
StatePublished - Nov 1 2003
Externally publishedYes

Fingerprint

Topotecan
Hematologic Neoplasms
Maximum Tolerated Dose
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Nausea
Vomiting
Diarrhea
Myeloproliferative Disorders
Mucositis
Blood Cell Count
Fatigue
Oral Administration
Appointments and Schedules
Research Design
Bone Marrow

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Beran, M., O'Brien, S., Thomas, D. A., Tran, H. T., Cortes-Franco, J. E., Giles, F., ... Kantarjian, H. M. (2003). Phase I study of oral topotecan in hematological malignancies. Clinical Cancer Research, 9(11), 4084-4091.

Phase I study of oral topotecan in hematological malignancies. / Beran, Miloslav; O'Brien, Susan; Thomas, Deborah A.; Tran, Hai T.; Cortes-Franco, Jorge E.; Giles, Francis; Estey, Elihu; Kantarjian, Hagop M.

In: Clinical Cancer Research, Vol. 9, No. 11, 01.11.2003, p. 4084-4091.

Research output: Contribution to journalArticle

Beran, M, O'Brien, S, Thomas, DA, Tran, HT, Cortes-Franco, JE, Giles, F, Estey, E & Kantarjian, HM 2003, 'Phase I study of oral topotecan in hematological malignancies', Clinical Cancer Research, vol. 9, no. 11, pp. 4084-4091.
Beran M, O'Brien S, Thomas DA, Tran HT, Cortes-Franco JE, Giles F et al. Phase I study of oral topotecan in hematological malignancies. Clinical Cancer Research. 2003 Nov 1;9(11):4084-4091.
Beran, Miloslav ; O'Brien, Susan ; Thomas, Deborah A. ; Tran, Hai T. ; Cortes-Franco, Jorge E. ; Giles, Francis ; Estey, Elihu ; Kantarjian, Hagop M. / Phase I study of oral topotecan in hematological malignancies. In: Clinical Cancer Research. 2003 ; Vol. 9, No. 11. pp. 4084-4091.
@article{1aa4071eb87d40e5b957ed33926931ab,
title = "Phase I study of oral topotecan in hematological malignancies",
abstract = "Purpose: In this Phase I, dose-seeking study, we investigated the dose-limiting toxicities (DLTs) and maximal tolerated dose (MTD) of oral topotecan in patients with hematological malignancies. Experimental Design: Patients with myelodysplastic syndromes, myeloproliferative disorders, or relapsed acute myelogenous leukemia were treated with 0.6-1.9 mg/m 2/day oral topotecan for 5 consecutive days on and 2 days off, for 3 weeks (15 doses/course) followed by 2-4 weeks of rest. The DLTs occurring during the first course of treatment were considered for defining the MTD. Preliminary results of antitumor activity were assessed by examining bone marrow status and peripheral blood cell counts. Results: All 26 patients enrolled in the study were evaluable for toxicity, and 24 patients were evaluable for response. A total of 54 courses were administered. The most frequently reported nonhematological toxicities (percentage of courses) were diarrhea (57{\%}), nausea/vomiting (50{\%}), fatigue (24{\%}), and mucositis (9{\%}). DLTs included grade 3 or 4 nausea/vomiting and diarrhea at 1.9 mg/m2/day. The MTD for oral topotecan in patients with hematological malignancies was defined at 1.4 mg/m2/day. Hematological toxicity was noted in all 26 patients and with all courses but was not considered dose-limiting. Four (17{\%}) patients achieved a complete response, and six (25{\%}) patients experienced hematological improvement. Conclusions: Protracted administration of oral topotecan is safe and well tolerated in patients with hematological malignancies. At the dose-schedule used, single-agent oral topotecan has a definite activity in patients with myelodysplastic syndrome and acute myelogenous leukemia and warrants further investigation alone or in combination with other agents.",
author = "Miloslav Beran and Susan O'Brien and Thomas, {Deborah A.} and Tran, {Hai T.} and Cortes-Franco, {Jorge E.} and Francis Giles and Elihu Estey and Kantarjian, {Hagop M.}",
year = "2003",
month = "11",
day = "1",
language = "English (US)",
volume = "9",
pages = "4084--4091",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Phase I study of oral topotecan in hematological malignancies

AU - Beran, Miloslav

AU - O'Brien, Susan

AU - Thomas, Deborah A.

AU - Tran, Hai T.

AU - Cortes-Franco, Jorge E.

AU - Giles, Francis

AU - Estey, Elihu

AU - Kantarjian, Hagop M.

PY - 2003/11/1

Y1 - 2003/11/1

N2 - Purpose: In this Phase I, dose-seeking study, we investigated the dose-limiting toxicities (DLTs) and maximal tolerated dose (MTD) of oral topotecan in patients with hematological malignancies. Experimental Design: Patients with myelodysplastic syndromes, myeloproliferative disorders, or relapsed acute myelogenous leukemia were treated with 0.6-1.9 mg/m 2/day oral topotecan for 5 consecutive days on and 2 days off, for 3 weeks (15 doses/course) followed by 2-4 weeks of rest. The DLTs occurring during the first course of treatment were considered for defining the MTD. Preliminary results of antitumor activity were assessed by examining bone marrow status and peripheral blood cell counts. Results: All 26 patients enrolled in the study were evaluable for toxicity, and 24 patients were evaluable for response. A total of 54 courses were administered. The most frequently reported nonhematological toxicities (percentage of courses) were diarrhea (57%), nausea/vomiting (50%), fatigue (24%), and mucositis (9%). DLTs included grade 3 or 4 nausea/vomiting and diarrhea at 1.9 mg/m2/day. The MTD for oral topotecan in patients with hematological malignancies was defined at 1.4 mg/m2/day. Hematological toxicity was noted in all 26 patients and with all courses but was not considered dose-limiting. Four (17%) patients achieved a complete response, and six (25%) patients experienced hematological improvement. Conclusions: Protracted administration of oral topotecan is safe and well tolerated in patients with hematological malignancies. At the dose-schedule used, single-agent oral topotecan has a definite activity in patients with myelodysplastic syndrome and acute myelogenous leukemia and warrants further investigation alone or in combination with other agents.

AB - Purpose: In this Phase I, dose-seeking study, we investigated the dose-limiting toxicities (DLTs) and maximal tolerated dose (MTD) of oral topotecan in patients with hematological malignancies. Experimental Design: Patients with myelodysplastic syndromes, myeloproliferative disorders, or relapsed acute myelogenous leukemia were treated with 0.6-1.9 mg/m 2/day oral topotecan for 5 consecutive days on and 2 days off, for 3 weeks (15 doses/course) followed by 2-4 weeks of rest. The DLTs occurring during the first course of treatment were considered for defining the MTD. Preliminary results of antitumor activity were assessed by examining bone marrow status and peripheral blood cell counts. Results: All 26 patients enrolled in the study were evaluable for toxicity, and 24 patients were evaluable for response. A total of 54 courses were administered. The most frequently reported nonhematological toxicities (percentage of courses) were diarrhea (57%), nausea/vomiting (50%), fatigue (24%), and mucositis (9%). DLTs included grade 3 or 4 nausea/vomiting and diarrhea at 1.9 mg/m2/day. The MTD for oral topotecan in patients with hematological malignancies was defined at 1.4 mg/m2/day. Hematological toxicity was noted in all 26 patients and with all courses but was not considered dose-limiting. Four (17%) patients achieved a complete response, and six (25%) patients experienced hematological improvement. Conclusions: Protracted administration of oral topotecan is safe and well tolerated in patients with hematological malignancies. At the dose-schedule used, single-agent oral topotecan has a definite activity in patients with myelodysplastic syndrome and acute myelogenous leukemia and warrants further investigation alone or in combination with other agents.

UR - http://www.scopus.com/inward/record.url?scp=0141455145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141455145&partnerID=8YFLogxK

M3 - Article

C2 - 14519630

AN - SCOPUS:0141455145

VL - 9

SP - 4084

EP - 4091

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 11

ER -